eFFECTOR Therapeutics, Inc.
OTC: EFTR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Davide Ruggero
- Employees
- 14
- Headquarters
- Solana Beach, United States
- IPO year
- 2021
- Market cap
- $941.0
- Website
- https://effector.com
Loading EFTR…
Loading profile data…Frequently asked questions about EFTR
What does eFFECTOR Therapeutics, Inc. (EFTR) do?
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is curren...
Where does EFTR trade?
eFFECTOR Therapeutics, Inc. (EFTR) trades on the Other OTC.
What sector is EFTR in?
eFFECTOR Therapeutics, Inc. (EFTR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of eFFECTOR Therapeutics, Inc.?
Davide Ruggero is the chief executive officer of eFFECTOR Therapeutics, Inc. (EFTR).
Where is eFFECTOR Therapeutics, Inc. headquartered?
eFFECTOR Therapeutics, Inc. is headquartered in United States.
Does EFTR pay a dividend?
eFFECTOR Therapeutics, Inc. (EFTR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EFTR go public?
eFFECTOR Therapeutics, Inc. (EFTR) completed its initial public offering in 2021.